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Tumor microenvironment is composed of tumor cells, ﬁbroblasts, and inﬁltrating immune cells, which all work together
and create an inﬂammatory environment favoring tumor progression. The present study aimed to investigate the role of the
desmoplastic stroma in pancreatic ductal adenocarcinoma (PDAC) regarding expression of inﬂammatory factors and inﬁltration
of immune cells and their impact on the clinical outcome. The PDAC tissues examined expressed signiﬁcantly increased levels of
immunomodulatory and chemotactic factors (IL-6, TGFβ, IDO, COX-2, CCL2, and CCL20) and immune cell-speciﬁc markers
corresponding to macrophages, myeloid, and plasmacytoid dendritic cells (DCs) as compared to controls. Furthermore, short-
time survivors had the lowest levels of DC markers. Immunostainings indicated that the diﬀerent immune cells and inﬂammatory
factors are mainly localized to the desmoplastic stroma. Therapies modulating the inﬂammatory tumor microenvironment to
promotetheattractionofDCsanddiﬀerentiationofmonocytesintofunctionalDCsmightimprovethesurvivalofPDACpatients.
1.Introduction
Many types of tumors have an inﬂammatory microenviron-
ment comparable to what is found in chronic inﬂammatory
responses, that is, are enriched in inﬂammatory cells and
mediators, transformed tissue, and increased angiogenesis
[1]. The inﬂammation is created by the interplay between
tumor cells and the surrounding stroma, for example, cancer
associated ﬁbroblasts (CAF), immune cells, and extracellular
matrix and gives rise to an environment favoring tumor
expansion [2]. The clinical relevance of the microenvi-
ronment regarding tumor progression is supported by
the correlations seen between poor outcome and CAFs,
angiogenesis and the composition and amount of inﬁltrating
inﬂammatory cells [3].
Pancreatic ductal adenocarcinoma (PDAC) is a common
gastrointestinal malignancy characterized by rapid progres-
sion, resulting in poor outcome and a 5-year survival rate of
less than 5% [4]. Like in most adenocarcinomas, PDAC has
a massive ﬁbrotic stoma, that is, desmoplasia [5–7], which
contributes to the local inﬂammatory environment at the
t u m o rs i t ea sw e l la ss y s t e m i c a l l y[ 8]. The microenvironment
foundinPDACsupportstumorgrowth,progression,andthe
recruitment of leukocytes, such as macrophages, dendritic
cells (DCs), T cells, and neutrophils [9–11]. Inﬁltration of
these cells has been detected in a variety of cancers [12, 13].2 Clinical and Developmental Immunology
Several studies have reported that blood DCs and tumor
inﬁltrating DCs exhibit phenotypic and functional abnor-
malities when isolated from tumor bearing animals and
patients with PDAC [14–16]. Given their pivotal role in
the adaptive immunity and tumor surveillance in healthy
individuals, this impairment might contribute to the tumor
escape from the immune system [17]. Increased numbers of
DCs have been associated with improved outcome in various
types of human cancers, and some studies have also pointed
out the DC maturation as a prognostic indicator [18]. We
have previously observed a correlation between survival time
for PDAC patients and the amount and phenotype of blood
DCs, which implicate the importance to maintain a func-
tional DC compartment [16, 19]. Diﬀerent inﬂammatory
mediators, for example, cyclooxygenase-2 (COX-2), IL-1, IL-
6, TGFβ and CXCL8, and their receptors are present in the
tumor milieu [20–22]. COX-2 is expressed by several solid
tumors,includingPDAC,andcorrelateswithtumorinvasion
and clinical outcome [22]. Moreover, COX-2 is believed
to have an inﬂuence on the DC impairment, and recent
ﬁndings have provided evidence that the COX-2 metabolite
prostaglandin E2 (PGE2) is involved in the upregulation of
indoleamine 2,3-dioxygenase (IDO) in DCs [23, 24]. IDO
expressiontransformsDCsintotolerogeniccellsthatactivate
regulatory T cells (Tregs), which have been shown to exist in
several types of cancers [13].
In the present study we found elevated levels of sev-
eral inﬂammatory factors, including CCL2, CCL20, TGFβ,
IDO, IL-6, and COX-2, in the PDAC tissue. Furthermore,
PDAC tissues had signiﬁcantly elevated levels of inﬁltrating
macrophages,cytotoxicTcells,andDCs.LowlevelsofMDC,
PDC, and mature DC markers were associated with poor
prognosis. Treatments that direct the inﬂammatory tumor
microenvironment to attract high levels of DCs could be
beneﬁcial for the clinical outcome of the PDAC patients.
2.MaterialandMethod
2.1. Patients and Controls Enrolled in the Study. Tumor tis-
sues were obtained from 30 PDAC patients undergo-
ing Whipple resection at Link¨ oping University Hospital,
Sweden. The patients did not receive any neoadjuvant
chemo/radiotherapy and the diagnosis was histologically
conﬁrmed by two pathologists. The control group consisted
of pancreatic tissue from ten individuals, seven individ-
uals deceased from hypothermia and three patients with
benign disease (adjacent pancreatic tissue with normal
histology was used in the study). The pancreatic tissues were
frozen immediately and cryopreserved in liquid nitrogen.
Paraﬃn-embedded tissue sections from patients and con-
trols were obtained from the department of Pathology at
Link¨ oping University Hospital, Sweden and the department
of Oncology-pathology, Karolinska Institutet, Stockholm,
Sweden. The PDACs were staged according to the 1997
International Union against Cancer classiﬁcation (TNM =
Tumor, Node, Metastasis), and the PDAC patients ranged
from T1–T4 (T1 (n = 3), T2 (n = 14), T3 (n = 12), and T4
(n = 1)), N0 (n = 6), N1 (n = 24), and M0 (n = 30) stage.
The study protocol and patient consent documents were
approved by the Regional Ethics committee in Link¨ oping,
Sweden (Dnr. M38-06).
2.2. RNA Extraction and Quantiﬁcation with Real-Time
PCR. Total RNA was prepared from the samples using
Trizol (Invitrogen) according to manufacturer’s protocol
and cDNA synthesized with SuperScript III Reverse Tran-
scriptase First-Strand cDNA Synthesis kit according to the
manufacturer’s protocol (Invitrogen). Quantitative PCR was
performed with Fast SYBR Green Master Mix (Version
09/2007; Applied Biosystems, Foster City, Calif, USA) on
7900 Fast Real-Time PCR system with 7900 System SDS
2.3 Software (Applied Biosystems) according to the man-
ufacturer’s protocol. Speciﬁc primers for CCL2, CCL20,
IL-6, TGFβ, CD1a, CD1c, CD68, CD163, CD208, CD209,
CD303(CyberGeneAB),andCOX-2(Invitrogen)wereused.
β-actin, and Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (CyberGene AB) were utilized as housekeeping
genes. The primers were designed using Primer Express
(Applied Biosystems). Real-time PCRs for the detection
of IDO and PD1 were performed using TaqMan Gene
Expression Assays (Applied Biosystems) according to the
manufacturer’s protocol. All reactions were performed in
triplicates including nontemplate controls and two endoge-
nous control probes. FAM conjugated, gene-speciﬁc assays
were Hs00984148 m1 (IDO), Hs00169472 m1 (PD1) and
the endogenous controls Hs01003267 m1 (HPRT1), and
Hs99999905 m1 (GAPDH). All reactions were performed in
triplicates including nontemplate controls. The results were
analyzed using the ΔΔCt method [25] and the data were
presented as the quantitative expression of each gene.
2.3. Immunohistochemical Staining of PDAC and Normal
Pancreatic Tissues. Formalin ﬁxed, paraﬃn-embedded sam-
ples of tumor tissue from PDAC patients (n = 30) and
normal pancreatic tissue (n = 10) were cut in 5μm
sections. The sections were then rehydrated and antigen
retrieval was performed in a microwave oven for 15min
(350W) using citrate buﬀer (pH 6.0). Endogenous perox-
idase was minimized by 10 minutes incubation in H2O2,
and nonspeciﬁc binding was avoided by incubating with
Background Sniper (Biocare Medical) or 1% bovine serum
albumin for 10min. The samples were immunostained
overnight with antibodies (Ab) for CXCL8 (1:25, Becton
Dickinson), COX-2 (1:200, CRM306B, Biocare Medical),
S100 (dilution 1:1000, Z 0311, Dako, Sweden), CD163
(dilution 1:10, ab74604), CD83 (dilution 1:50, ab64875),
CD8 (dilution 1:600, ab4055), IL-1α (1:40, ab7632), CCL2
(1:1000, ab73680), and CCL20 (1:40, ab9829) (Abcam,
UK). The sections were then incubated with alkaline phos-
phatase conjugated anti-mouse or anti-rabbit secondary Ab
(Jackson ImmunoResearch) for one hour or by using LSAB2
System-HRP kit (K0675, Dako) containing biotinylated
link and streptavidin-conjugated HRP according to the
manufacturer’s protocol. Alkaline phosphatase was detected
by Vulcan fast red chromogen 2 solution (Biocare Medical)
according to the manufacture’s protocol. HRP was detectedClinical and Developmental Immunology 3
by development in Tris-buﬀer containing diaminobenzi-
dine tetrahydrochloride (DAB) (Saveen-Werner AB) and
10μL of 30% H2O2. Counter-staining was performed
with methyl green solution (0.1M sodium Acetate buﬀer,
pH 4.2) containing 1% methyl-green (Sigma Aldrich) or
hematoxylin.
2.4. Quantiﬁcation of Inﬂammatory Factors and Immune
Cells in Tumor Tissue. The amount of CD163, CD8,
CD83, and S100 immunoreactive cells and the COX-
2 ratio between tumor cells and stroma were analyzed
using Quantimet 500MC image processing analysis systems
linked to a Leica DM LB microscope (Leica Microsys-
tems) supported by Leica QWin software version 3 (Leica
Microsystems). CD163, S100, CD83, and CD8 positive
cells were manually marked in 20 randomly chosen ﬁelds
(×40 magniﬁcation) using automated standard operation
sequences created by QUIPS (Leica Microsystems), an
interactive programming system included in the Leica
QWin software. The number of immunoreactive cells/μm2
pancreatic tissue was calculated. To evaluate the COX-
2 ratio between tumor cells and stroma, PDAC tissues
were immunohistochemically stained with a combination
of rabbit anti-human COX-2 and mouse anti human Ki-67
Ab, followed by alkaline phosphatase- and HRP-conjugated
secondary Ab and detected as previously described. Ten
randomly selected ﬁelds were chosen and areas of double
positive cell structures (tumor structures) were marked
using an automated standard operation sequence created by
QUIPS and compared to nonproliferative COX-2 positive
stroma.
2.5. Statistics. The statistical analysis was performed with
GraphPadPrism5(GraphPadSoftware,LaJolla,Calif,USA).
A P-value < 0.05 was considered statistically signiﬁcant
and error bars throughout indicate standard error of the
mean (SEM). Nonparametric data was analyzed using the
Wilcoxon matched pairs test followed by Mann-Whitney
test. Survival curve was analyzed by the Kaplan-Meier
survival method, and statistical signiﬁcance was determined
using Log-rank (Mantel-Cox) test and P value < 0.05 was
considered statistically signiﬁcant.
3. Result
3.1. PDAC Microenvironment Contains Elevated Gene and
Protein Expression Levels of Inﬂammatory Factors. We exam-
ined the gene expression levels of several inﬂammatory
f a c t o r sb yq P C Ri nP D A Ct i s s u e sa n dc o m p a r e dt h e mt o
the levels found in pancreatic tissues from the controls. IL-
6( P = 0.023), COX-2 (P<0.001), CCL2 (P = 0.035),
CCL20 (P<0.001), TGFβ (P = 0.016), and IDO (P =
0.003) gene expression levels were all signiﬁcantly increased
in PDAC tissues compared to controls (Figures 1(a)–1(f)).
Geneexpressionofprogrammeddeath-1receptor(PD1)was
not detected in any of the control samples (n = 10), but
detected in 40% of the tumor samples (n = 30) (data not
shown).
3.2. Distribution of Inﬂammatory Factors in Tumor Cells and
Stroma in PDAC Tissues. The position of the inﬂammatory
factors detected in the tumor microenvironment was done
by immunohistochemistry (IHC). We stained PDAC and
normal pancreatic tissues with Saﬀron and Hematoxylin,
known to visualize ﬁbrotic tissues. This staining demon-
strated that the tumor cells were surrounded by a massive
desmoplastic stroma in PDAC (Figures 2(a) and 2(b)). IL-
1α was exclusively located in tumor cells while normal
pancreatic tissue stained negative (Figure 3(a)). CCL2 was
expressed by ﬁbrotic stroma and Langerhans islets, in both
PDAC and healthy pancreatic tissues. CXCL8 and CCL20
were exclusively expressed by PDAC tissue and mainly
localized to the stroma cells, but CCL20 was also detected in
tumorcells(Figures3(b)–3(d)).WefoundCOX-2expression
to be restricted to PDAC samples, where several cell types,
for example, tumor cells, CAFs, Langerhans Islet cells,
and inﬁltrating immune cells in the tumor expressed this
inﬂammatory mediator with signiﬁcantly higher expression
in the stroma than in tumor nests (P = 0.028) (Figures 3(e)
and 3(f)). These ﬁndings indicate that the stroma, that is,
nonneoplastic tissue, constitutes an important contributor
to the inﬂammation seen in the tumor microenvironment in
PDAC.
3.3. PDAC Tissue Shows Elevated Gene Expression of Markers
Associated with the Expression of Macrophages and Dendritic
Cell Subtypes. The presence and activation status of tumor
inﬁltrating immune cells was assessed by qPCR using cell-
speciﬁc markers unique for DCs, or macrophages. We found
signiﬁcantly increased levels of macrophages as measured by
CD163 (P<0.001) (Figure 4(a)) and CD68 (P<0.001)
(Figure 4(b)), myeloid DCs as measured by CD1a (P =
0.032) and CD1c (P<0.001) (Figures 4(c) and 4(d)), and
plasmacytoid DCs as measured by CD303 (P = 0.007)
(Figure 4(e)). The DCs displayed an activated phenotype
with signiﬁcantly increased CD83 (P<0.001), CD208 (P =
0.008), and decreased CD209 (P<0.001) (Figures 4(f)–
4(h)). Of note, we cannot rule out that a fraction of the
CD209 expression detected is due to other cells than DCs as
a small subpopulation of tissue macrophages can express this
lectin [26].
3.4. Enhanced Levels of Inﬁltrating Immune Cells Such As
Macrophages, Dendritic Cells, and Cytotoxic T Cells in the
PDAC Stroma. We assessed the presence of macrophages,
DCs, mature DCs, and cytotoxic T cells in the PDAC
microenvironment by immunostaining. Inﬁltrating CD163
positive macrophages were found in the tumor stroma, and
the levels were signiﬁcantly higher than in the control group
(P<0.001) (Figures 5(a) and 5(e)). S100 positive DCs
were signiﬁcantly increased in PDAC compared to normal
pancreas (P = 0.018). The majority of S100 positive cells
in PDAC tissue were located in the ﬁbrous stroma, often
in close relation to tumor nests, whereas DCs in healthy
pancreas tissues were mainly found in the Langerhans islets
(Figures 5(b) and 5(e)). The inﬁltration of CD83 positive
matureDCsvariedfromlowtomassivebetweenthediﬀerent4 Clinical and Developmental Immunology
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Figure 1: Elevated gene expression levels of inﬂammatory factors in PDAC tissue. RNA was extracted from PDAC (n = 30) and normal
pancreatic tissue samples (n = 10) and assessed for relative gene expression levels of the inﬂammatory factors, IL-6 (a), COX-2 (b), CCL2
(c), CCL20 (d) TGFβ (e), and IDO (f). ∗P<0.05, ∗∗P<0.05, ∗∗∗P<0.001.Clinical and Developmental Immunology 5
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Figure 2: PDAC tissues contain an extensive ﬁbrotic component. Normal pancreas from individuals deceased from hypothermia, and PDAC
tissueswerestainedusingSaﬀronandHematoxylin.PhotographsshowthestainingforPDAC(a)andnormalpancreas(b),theﬁbrotictissue
is visualized as orange. Size bar 20μm.
PDAC patients but showed signiﬁcantly increased numbers
comparedtohealthypancreastissue(P = 0.004).Thehighest
extent of CD83 positive dendritic cells in PDAC were found
in the ﬁbrous stroma (Figures5(c) and 5(e)). Cytotoxic
CD8+ T cells (CTLs) were not found in healthy pancreas,
but PDAC tissues had an inﬁltration of CD8+ T cells in the
ﬁbrous stroma surrounding the tumor nests. The numbers
of CD8+ T cells found in PDAC samples were signiﬁcantly
higher than in controls (P<0.001) (Figures 5(d) and
5(e)). To make sure that ischemia induced by the surgical
procedure was not inﬂuencing the amount of inﬁltrating
immune cells in the tissue samples, we compared Whipple
resected pancreatic tissue from patients with cystic lesions;
tumor adjacent pancreatic tissue (with normal histology) as
well as pancreatic tissues obtained from individuals deceased
from hypothermia (data not shown). We did not see any
diﬀerence in the amount of inﬂammatory cells or expression
levels of inﬂammatory markers for patients with or without
stent (data not shown), which is supported by the literature
showing only superﬁcial inﬁltration of inﬂammatory cells at
the location of nondrug delivery stents [27–29]. To eliminate
jaundice as a factor modulating the immune cells in our
study, we compared the patients’ blood bilirubin levels with
the levels of the immune cell markers assessed in this study
and found no correlation.
3.5. PDAC Patients with Higher Levels of Dendritic Cells and
Macrophages with CD163 Dominating Phenotype Had the
Longest Survival Time. The impacts DCs and macrophages
have on patient survival were tested by dividing the patients
into three groups based on the survival time after tumor
resection (short = less than one year (n = 9), moderate
= between 1 and 2 years (n = 10) and long = more than
two years (n = 11)). The short-time survivors expressed
signiﬁcantly lower gene levels of myeloid DC (CD1c+) and
plasmacytoid DC (CD303+) markers as compared to the
moderate survivors (P = 0.017 (CD1c) and P<0.001
(CD303)). Higher gene expression levels were also observed
among the long time survivors, but the diﬀerence was not
signiﬁcant (Figures 6(a) and 6(b)). The number of S100
positive DCs in PDAC tissue was higher in the patients
surviving more than 2 years compared to patients surviving
less than one year, but the diﬀerence was not signiﬁcant
(P = 0.06) (data not shown). The gene expression levels of
theDCactivationmarkersCD208andCD209showedhigher
levels of both tumor inﬁltrated mature and immature DCs
among the moderate (P = 0.07 (CD208) and P = 0.008
(CD209)) and long-time survivors (P = 0.012 (CD208)
and P = ns (CD209)) as compared to short-time survivors
(Figures 6(c) and 6(d)). The short time survivors were
also found to have tumors expressing the lowest levels of
the macrophage marker CD163 compared to the moderate
survivors (P = 0.014), and the same tendency was observed
among the long-time survivors but the diﬀerence was not
signiﬁcant (Figure 6(e)). The tumor expression levels of
CD68, another macrophage marker, indicated the long-time
survivors to express the lowest levels of CD68+ macrophages
(Figure 6(f)). To further investigate the clinical outcome
of the expression of CD68 and CD163 by macrophages,
we divided the patients into two groups based on if their
main gene expression was CD68 or CD163. Patients with
a dominating gene expression of CD163 were presented
with signiﬁcantly better clinical outcome than patients with
a CD68 dominating macrophage population (P = 0.017)
(Figure 6(g)).
4. Discussion
Thecompositionofthetumormicroenvironmentisessential
for the tumor development and will inﬂuence the ability of
the immune system to mount a defense against the tumor.
PDAC tissues contained several types of inﬂammatory
immune cells, that is, macrophages, MDCs, PDCs, and
CTLs, besides high levels of inﬂammatory factors including
IL-1α, IL-6, COX-2, TGFβ, CXCL8, CCL2, and CCL20.
The inﬂammatory factors produced by tumor and stroma
cells, including immune cells, CAFs, and Langerhans islet
cells, create an environment that could support survival
and progression of the malignant cells by altering the
inﬂammatory balance in favor of the tumor.6 Clinical and Developmental Immunology
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Figure 3: The majority of inﬂammatory factors in PDAC microenvironment were expressed by the stroma cells. Human PDAC tissue
sections were immunostained with anti-COX-2, -CCL20, -CCL2, -CXCL8, and -IL-1α antibodies (abs) followed by alkaline phosphatase-
conjugated secondary abs and visualized with fast red chromogen. Photographs show the staining (red) for (a) IL-1α positive tumor
structures, (b) CXCL8 positive tumor stroma, (c) CCL2 positive ﬁbrotic cells, (d) CCL20 positive tumor and stromal cells, and (e) COX-2
positive tumor cells and stroma. Size bar 20μm. (f) To evaluate the ratio between tumor cell and stroma expressed COX-2, PDAC tissue
sections were immunohistochemically stained with anti-COX-2 (red) and anti-Ki-67 abs (brown), followed by alkaline phosphatase- and
HRP-conjugated secondary abs and detected using fast red chromogen and DAB, respectively. Areas of double positive cells (tumor nests)
were compared to nonproliferative COX-2 positive stroma using a computerized image processing analysis system. ∗P<0.05.
In healthy human pancreas the Langerhans islets were
foundtobethemainreservoirofDCsand,toourknowledge,
this has previously only been reported in mice [30]. An
obvious relocation of DCs was seen in the PDAC tissues,
where most DCs were located in the ﬁbrotic stroma. The
expression of DCs were found to be higher in the tumors
than in normal healthy pancreas, but in general the PDAC
tumors showed very low levels of both MDCs and PDCs,
and a shortage of DCs, mature or immature, was associated
with poor clinical outcome. The low levels of DCs and the
location in the tumor stroma conﬁrmed previous ﬁndings
by Dallal et al. [31], but with the use of gene-speciﬁc
markers we have further extended these ﬁndings to include
immunomodulatory and chemotactic factors. Furthermore,
we were able to show a connection between the DC
inﬁltration and the clinical outcome of the patients.
The chemokines produced by the ﬁbrotic stroma in
PDAC tumors, including CXCL8 and CCL20, have previ-
ously been shown to initiate the migration of DCs to this
site [32]. Moreover, CXCL8 derived from tumor cells have
been shown to retain DCs in the tumor resulting in deﬁcient
migration to the lymph nodes and also impaired immune
response against the cancer [33]. This is also supported by
our ﬁndings of elevated levels of mature DCs expressing
the phenotypic maturation markers CD83 and CD208 in
addition to decreased levels of CD209. Nevertheless, patients
with low levels of inﬁltrating CD208 positive DCs had the
shortest survival time among the PDAC patients which
is in accordance with ﬁndings in melanoma [34]. This
could indicate an important role for the composition of the
inﬂammatory tumor microenvironment and its ability to
retain and mature the DCs.
PDCs are normally found in blood but can also be
found at sites of chronic inﬂammation including cancers
[35]. PDAC tumors have been shown to express high levels
of CXCL12 and CCL2, which could promote PDC migration
into the tumor [36, 37]. This is in accordance with our data
showing the presence of PDCs in PDAC tissue and the lack
of PDCs in healthy pancreatic tissue.
IDO expressed by DCs or cancer cells have been shown
to suppress the immune response to tumors by establishing
immunological tolerance [38]. Furthermore, the expression
of IDO in ovarian, endometrial, and colon cancer has been
correlatedtopoorclinicaloutcome[39].TheCOX-2product
PGE2 isknowntobeaninducerofIDOexpressioninantigen
presenting cells and inhibition of COX-2 expression both in
vitro and in vivo reduced the expression of IDO [40]. This is
in accordance with our data showing increased expression of
bothCOX-2andIDOinthePDACtissues.Consequently,the
elevated levels of IDO detected in the PDAC tumors could
be a contributing factor to the lack of an eﬃcient immune
response against the tumor.
Another factor associated with immune tolerance, TGFβ,
expressedbytumorcellsandtumorinﬁltratingDCshasbeen
shown to promote the expansion of natural occurring Tregs
(nTregs) [41, 42]. In the present study, PDAC but not healthy
pancreatic tissue expressed TGFβ which might contribute
to the immune suppression by promoting the expansion
of nTregs in the tumor microenvironment and this needs
further investigation.
ThenegativeimmunoregulatoryreceptorPD1,expressed
by activated T cells, was detected in 40% of the PDAC
tumors. The presence of PD1 positive immune cells has been
shown to be associated with adverse pathology and poor
outcome in patients with renal cell carcinoma [43, 44]a n d
might also be involved in the impaired immune response
against PDAC tumors.
Macrophages are derived from progenitors, that is,
monocytes existing in the circulation, and are recruited to
tissues under the inﬂuence of CCL2 [45], which was found
elevated in PDAC tissue in the present study. Macrophages
may enhance the tumor growth as they secrete VEGF-A,8 Clinical and Developmental Immunology
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Figure 4: Elevated gene expression levels of markers of inﬁltrating immune cells in PDAC tissue. RNA was obtained from PDAC (n =
30) and normal pancreatic tissue samples (n = 10) and assessed for relative gene expression levels of markers expressed by (a and b)
macrophages (CD68 and CD163), (c and d) myeloid dendritic cells (CD1a and CD1c), (e) plasmacytoid dendritic cells (CD303), and (f–h)
DC maturation/activation status markers (CD83, CD208 and CD209). ∗P<0.05, ∗∗P<0.05, ∗∗∗P<0.001.Clinical and Developmental Immunology 9
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Figure 5: PDAC tissues show inﬁltration of immune cells such as macrophages, dendritic cells, and CTLs. PDAC and healthy pancreatic
tissue samples were immunohistochemically stained with anti CD163, S100, CD83, and CD8 antibodies (abs) followed by biotin-conjugated
secondary abs and streptavidin-HRP complex. Peroxidase was detected using DAB chromogen. The amount CD163 (a), S100 (b), CD83
(c), and CD8 (d) positive cells/μm2 were calculated from 20 randomly selected ﬁelds using a computerized image processing analysis system
linked to a microscope. (e) The micrographs show expression and location of CD163, S100, CD83, and CD8 positive cells in the PDAC and
healthy pancreatic tissues. Size bar 20μm. ∗P<0.05, ∗∗P<0.05, ∗∗∗P<0.001.10 Clinical and Developmental Immunology
0
0.05
0.10
0.15
C
D
1
c
g
e
n
e
e
x
p
r
e
s
s
i
o
n
∗
<1 1-2 >2
(Years)
(a)
0
0.05
0.10
0.15
g
e
n
e
e
x
p
r
e
s
s
i
o
n
C
D
3
0
3
∗ ∗∗
<1 1-2 >2
(Years)
(b)
0
0.02
0.04
0.06
C
D
2
0
8
g
e
n
e
e
x
p
r
e
s
s
i
o
n
∗
<1 1-2 >2
(Years)
(c)
0
0.02
0.04
0.06
∗
g
e
n
e
e
x
p
r
e
s
s
i
o
n
C
D
2
0
9
<1 1-2 > > 2
(Years)
(d)
<1 1-2 >2
0
0.2
0.4
0.6
0.8
C
D
1
6
3
g
e
n
e
e
x
p
r
e
s
s
i
o
n
∗
(Years)
(e)
<1 1-2 >2
0
0.5
1
1.5
2
2.5
g
e
n
e
e
x
p
r
e
s
s
i
o
n
C
D
6
8
(Years)
(f)
0 500 1000 1500 2000
0
20
40
60
80
100
CD68 high
CD163 high
P
e
r
c
e
n
t
s
u
r
v
i
v
a
l
∗
Days after surgery
(g)
Figure 6: The expression levels of dendritic cell and macrophage markers might predict the PDAC patient survival. The PDAC patients were
divided into three groups based on their survival time after tumor resection (less than one year (n = 9 ) ,b e t w e e n1a n d2y e a r s( n = 10),
and more than two years (n = 11)). The gene expressions of CD1c (a), CD303 (b), CD208 (c), CD209 (d), CD163 (e), and CD68 (f) were
compared between each group. The patients were also divided into two groups based on if the main expression of macrophage markers was
CD68 (n = 12) or CD163 (n = 18) (g). Log-rank (Mantel Cox) test was used for calculation of P value. ∗P<0.05, ∗∗P<0.05, ∗∗∗P<0.001.
VEGF-C, and FGF, which are known to contribute to angio-
genesis in tumor and also to increase the metastatic potential
of tumor cells [9]. When inﬁltrating the tumor microen-
vironment, these cells are referred to as tumor-associated
macrophages (TAMs). TAMs are important inﬂammatory
cells correlating with tumor progression and bad prognosis
in, for example, breast, lung, and cervix cancer {Leek, 2000
#160; Zhang, #157; Pollard, 2004 #151}. Our data suggest
that high gene expression levels of CD68 might be associated
withpoorprognosis,thoughnonsigniﬁcant,whilehighlevels
of CD163 were found among the patients with the best clin-
ical outcome, which could point toward the presence of two
diﬀerent types of TAMs with opposite functions. This was
supported by our ﬁndings pointing to a survival advantage
for patients with a CD163 dominating macrophage pheno-
type. Moreover, the PDAC tumors expressed macrophage
markers to a higher extent than DC markers which might at
least partly be explained by the increased expression of IL-6Clinical and Developmental Immunology 11
which has been shown by Chomarat et al. [46]t op r o m o t e
the diﬀerentiation of monocytes into macrophages at the
expense of DCs [46]. We have previously identiﬁed IL-1α
to be the main tool used by the tumor cells to activate
CAFs to produce several inﬂammatory factors (e.g., IL-6,
CCL20, CXCL8, COX-2, and VEGF-A), and this could be
one mechanism the tumor cells use to escape elimination
by the immune system. Blocking the IL-1 signaling cascade
using synthetic IL-1RA (Kineret) drastically reduced the
expression of the inﬂammatory factors in vitro [47], and
treatment with IL-1 antagonist might thus have the potential
to downregulate the levels of immunomodulatory factors in
PDAC tumors.
This study points to the importance of the ﬁbrotic
stroma in the production of inﬂammatory factors and
accommodationofimmunecellsinPDACtumors.Therapies
targeting the desmoplastic stroma and/or inﬂammatory
factors such as IL-6, COX-2, CXCL8, and TGFβ might have
the potential to manipulate the tumor microenvironment to
beneﬁt attraction of DCs and diﬀerentiation of monocytes
into functional DCs which could aﬀect the clinical outcome
for the PDAC patients.
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